Rituximab Terminated Phase 1 Trials for Testicular Lymphoma / Recurrent Adult Burkitt Lymphoma / Intraocular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Small Lymphocytic Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Small Intestine Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Splenic Marginal Zone Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / B-Cell Chronic Lymphocytic Leukemia / B-cell Adult Acute Lymphoblastic Leukemia / Recurrent Mycosis Fungoides/Sezary Syndrome / Waldenström's Macroglobulinemia (WM) / Recurrent Marginal Zone Lymphoma / Chronic Lymphocytic Leukemia (CLL) - Refractory / Recurrent Adult Acute Lymphoblastic Leukemia / Nodal marginal zone B-cell lymphomas / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Refractory Hairy Cell Leukemia Treatment

IndicationsStatusPurposePhase
TerminatedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT02168907CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
NCT01078974Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia